(DSFIR) DSM-Firmenich - Overview
Stock: Vitamins, Flavors, Enzymes, Probiotics, Fragrances
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.67% |
| Yield on Cost 5y | 2.48% |
| Yield CAGR 5y | 25.00% |
| Payout Consistency | 98.8% |
| Payout Ratio | 80.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Relative Tail Risk | -6.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.63 |
| Alpha | -31.93 |
| Character TTM | |
|---|---|
| Beta | -0.008 |
| Beta Downside | -0.004 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.95% |
| CAGR/Max DD | -0.32 |
Description: DSFIR DSM-Firmenich December 19, 2025
DSM-Firmenich AG (ticker DSFIR) is a Swiss-based, publicly-listed company founded in 1902 and headquartered in Kaiseraugst. It operates globally across Europe, the Middle East & Africa, North America, Latin America, China and the rest of Asia, and is classified under the GICS sub-industry “Personal Care Products.”
The business is organized into four segments: Perfumery & Beauty (scents from natural, synthetic and biotech sources); Taste, Texture & Health (flavors, natural extracts, sugar-reduction solutions, food enzymes, hydrocolloids, plant-based proteins, and colorants); Health, Nutrition & Care (early-life nutrition, dietary supplements, pharma-grade APIs, vitamins, minerals, carotenoids, nutraceuticals, probiotics, post-biotics, biomedical materials and regulatory services); and Animal Nutrition & Health (animal proteins, vitamins, performance enhancers and data-driven precision services).
Since the DSM-Firmenich merger in 2023, the combined entity reported roughly €15.6 billion of revenue and an adjusted EBITDA margin of about 13 % for FY 2023, with R&D expenditures running near €800 million (≈5 % of sales). The company’s market-capitalisation hovers around CHF 30 billion, and its dividend yield is currently ~2.3 %.
Key growth drivers for DSM-Firmenich include: (1) accelerating consumer demand for natural, clean-label ingredients and plant-based proteins, which is expanding the global flavor-and-fragrance market at a CAGR of ~5 %; (2) tightening food-safety and sustainability regulations that increase spend on regulatory-service offerings; and (3) rising pet-food and livestock-nutrition spending in emerging markets, which is outpacing overall animal-protein growth.
For a data-rich, quantitative view of DSM-Firmenich’s valuation and risk profile, you may find it useful to explore the company’s page on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 718.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.43 > 1.0 |
| NWC/Revenue: 44.52% < 20% (prev 26.07%; Δ 18.45% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.59b > Net Income 718.0m |
| Net Debt (2.61b) to EBITDA (2.21b): 1.18 < 3 |
| Current Ratio: 2.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (263.5m) vs 12m ago -0.57% < -2% |
| Gross Margin: 34.13% > 18% (prev 0.27%; Δ 3386 % > 0.5%) |
| Asset Turnover: 39.95% > 50% (prev 37.96%; Δ 1.99% > 0%) |
| Interest Coverage Ratio: 9.48 > 6 (EBITDA TTM 2.21b / Interest Expense TTM 120.0m) |
Altman Z'' 3.55
| A: 0.18 (Total Current Assets 9.21b - Total Current Liabilities 3.42b) / Total Assets 32.32b |
| B: 0.33 (Retained Earnings 10.74b / Total Assets 32.32b) |
| C: 0.03 (EBIT TTM 1.14b / Avg Total Assets 32.56b) |
| D: 1.01 (Book Value of Equity 10.92b / Total Liabilities 10.81b) |
| Altman-Z'' Score: 3.55 = A |
Beneish M -3.29
| DSRI: 0.96 (Receivables 2.77b/2.77b, Revenue 13.01b/12.46b) |
| GMI: 0.80 (GM 34.13% / 27.19%) |
| AQI: 0.91 (AQ_t 0.54 / AQ_t-1 0.60) |
| SGI: 1.04 (Revenue 13.01b / 12.46b) |
| TATA: -0.03 (NI 718.0m - CFO 1.59b) / TA 32.32b) |
| Beneish M-Score: -3.29 (Cap -4..+1) = AA |
What is the price of DSFIR shares?
Over the past week, the price has changed by +6.53%, over one month by +3.07%, over three months by +0.66% and over the past year by -24.45%.
Is DSFIR a buy, sell or hold?
What are the forecasts/targets for the DSFIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102 | 44.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 63.5 | -10% |
DSFIR Fundamental Data Overview February 03, 2026
P/E Trailing = 26.6912
P/E Forward = 14.9701
P/S = 1.2862
P/B = 0.7807
P/EG = 0.3764
Revenue TTM = 13.01b EUR
EBIT TTM = 1.14b EUR
EBITDA TTM = 2.21b EUR
Long Term Debt = 5.18b EUR (estimated: total debt 5.43b - short term 250.0m)
Short Term Debt = 250.0m EUR (from shortTermDebt, last quarter)
Debt = 5.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.61b EUR (from netDebt column, last quarter)
Enterprise Value = 20.98b EUR (18.41b + Debt 5.43b - CCE 2.86b)
Interest Coverage Ratio = 9.48 (Ebit TTM 1.14b / Interest Expense TTM 120.0m)
EV/FCF = 23.82x (Enterprise Value 20.98b / FCF TTM 881.0m)
FCF Yield = 4.20% (FCF TTM 881.0m / Enterprise Value 20.98b)
FCF Margin = 6.77% (FCF TTM 881.0m / Revenue TTM 13.01b)
Net Margin = 5.52% (Net Income TTM 718.0m / Revenue TTM 13.01b)
Gross Margin = 34.13% ((Revenue TTM 13.01b - Cost of Revenue TTM 8.57b) / Revenue TTM)
Gross Margin QoQ = 36.56% (prev 36.56%)
Tobins Q-Ratio = 0.65 (Enterprise Value 20.98b / Total Assets 32.32b)
Interest Expense / Debt = 0.68% (Interest Expense 37.0m / Debt 5.43b)
Taxrate = 18.40% (61.0m / 331.5m)
NOPAT = 928.6m (EBIT 1.14b * (1 - 18.40%))
Current Ratio = 2.69 (Total Current Assets 9.21b / Total Current Liabilities 3.42b)
Debt / Equity = 0.25 (Debt 5.43b / totalStockholderEquity, last quarter 21.35b)
Debt / EBITDA = 1.18 (Net Debt 2.61b / EBITDA 2.21b)
Debt / FCF = 2.96 (Net Debt 2.61b / FCF TTM 881.0m)
Total Stockholder Equity = 21.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.20% (Net Income 718.0m / Total Assets 32.32b)
RoE = 3.27% (Net Income TTM 718.0m / Total Stockholder Equity 21.93b)
RoCE = 4.20% (EBIT 1.14b / Capital Employed (Equity 21.93b + L.T.Debt 5.18b))
RoIC = 3.88% (NOPAT 928.6m / Invested Capital 23.92b)
WACC = 4.67% (E(18.41b)/V(23.84b) * Re(5.88%) + D(5.43b)/V(23.84b) * Rd(0.68%) * (1-Tc(0.18)))
Discount Rate = 5.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.43%
[DCF Debug] Terminal Value 88.15% ; FCFF base≈829.8m ; Y1≈991.7m ; Y5≈1.57b
Fair Price DCF = 170.6 (EV 45.87b - Net Debt 2.61b = Equity 43.26b / Shares 253.6m; r=5.90% [WACC]; 5y FCF grow 20.83% → 2.90% )
EPS Correlation: 86.05 | EPS CAGR: 64.39% | SUE: -1.00 | # QB: 0
Revenue Correlation: 41.44 | Revenue CAGR: 8.98% | SUE: -0.05 | # QB: 0
EPS next Year (2026-12-31): EPS=3.81 | Chg30d=-0.311 | Revisions Net=-13 | Growth EPS=+0.7% | Growth Revenue=+0.9%